U.S., July 1 -- ClinicalTrials.gov registry received information related to the study (NCT07674823) titled 'Phase 1 Study Of KITE-753 in R/R B-Cell ALL' on June 26.
Brief Summary: The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.
Study Start Date: Dec. 31, 2026
Study Type: INTERVENTIONAL
Condition:
B-cell Acute Lymphoblastic Leukemia
Intervention:
DRUG: KITE-753
Given by infusion
Recruitment Status: NOT_YET_RECRUITING
Sponsor: M.D. Anderson Cancer Center
Published by HT Digital Content Services with permission from Health Daily Digest....